U.S. flag

An official website of the United States government

NM_000061.3(BTK):c.863G>A (p.Arg288Gln) AND not specified

Germline classification:
Pathogenic (1 submission)
Last evaluated:
Feb 5, 2019
Review status:
1 star out of maximum of 4 stars
criteria provided, single submitter
Somatic classification
of clinical impact:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Somatic classification
of oncogenicity:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Record status:
current
Accession:
RCV001001062.8

Allele description [Variation Report for NM_000061.3(BTK):c.863G>A (p.Arg288Gln)]

NM_000061.3(BTK):c.863G>A (p.Arg288Gln)

Gene:
BTK:Bruton tyrosine kinase [Gene - OMIM - HGNC]
Variant type:
single nucleotide variant
Cytogenetic location:
Xq22.1
Genomic location:
Preferred name:
NM_000061.3(BTK):c.863G>A (p.Arg288Gln)
HGVS:
  • NC_000023.11:g.101359324C>T
  • NG_009616.1:g.31901G>A
  • NM_000061.3:c.863G>AMANE SELECT
  • NM_001287344.2:c.965G>A
  • NM_001287345.2:c.863G>A
  • NP_000052.1:p.Arg288Gln
  • NP_000052.1:p.Arg288Gln
  • NP_001274273.1:p.Arg322Gln
  • NP_001274274.1:p.Arg288Gln
  • LRG_128t1:c.863G>A
  • LRG_128:g.31901G>A
  • LRG_128p1:p.Arg288Gln
  • NC_000023.10:g.100614312C>T
  • NM_000061.2:c.863G>A
Protein change:
R288Q
Links:
dbSNP: rs1555978277
NCBI 1000 Genomes Browser:
rs1555978277
Molecular consequence:
  • NM_000061.3:c.863G>A - missense variant - [Sequence Ontology: SO:0001583]
  • NM_001287344.2:c.965G>A - missense variant - [Sequence Ontology: SO:0001583]
  • NM_001287345.2:c.863G>A - missense variant - [Sequence Ontology: SO:0001583]

Condition(s)

Synonyms:
AllHighlyPenetrant
Identifiers:
MedGen: CN169374

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...

Assertion and evidence details

Submission AccessionSubmitterReview Status
(Assertion method)
Clinical Significance
(Last evaluated)
OriginMethodCitations
SCV001158183ARUP Laboratories, Molecular Genetics and Genomics, ARUP Laboratories
criteria provided, single submitter

(ARUP Molecular Germline Variant Investigation Process)
Pathogenic
(Feb 5, 2019)
germlineclinical testing

Citation Link

Summary from all submissions

EthnicityOriginAffectedIndividualsFamiliesChromosomes testedNumber TestedFamily historyMethod
not providedgermlineunknownnot providednot providednot providednot providednot providedclinical testing

Details of each submission

From ARUP Laboratories, Molecular Genetics and Genomics, ARUP Laboratories, SCV001158183.1

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1not providednot providednot providednot providedclinical testingnot provided

Description

The BTK c.863G>A; p.Arg288Gln variant (rs1555978277) is reported in the literature in numerous individuals with symptoms or a diagnosis of X-linked agammaglobulinemia (Abbott 2013, Conley 1998, Fiorini 2004, Futatani 2001, Lee 2010, Plebani 2002). This variant is absent from general population databases (Exome Variant Server, Genome Aggregation Database), indicating it is not a common polymorphism, and it is reported as pathogenic by multiple laboratories in ClinVar (Variation ID: 492813). The arginine at codon 288 is highly conserved, and computational analyses (SIFT, PolyPhen-2) predict that this variant is deleterious. Further, this variant occurs in the phosphotyrosine-binding pocket of a functional important SH2 domain and in vitro assays indicate that it disrupts binding to phosphorylated peptides (Tzeng 2000). Another variant at the same codon (p.Arg288Trp) has been reported in individuals with X-linked agammaglobulinemia and is considered pathogenic (Fiorini 2004, Plebani 2002, Tzeng 2000). Based on available information, the p.Arg288Gln variant is considered to be pathogenic. References: Abbott JK et al. Coding-region alterations in BTK do not universally cause X-linked agammaglobulinemia. J Allergy Clin Immunol. 2013 Nov;132(5):1246-8. Conley ME et al. Mutations in btk in patients with presumed X-linked agammaglobulinemia. Am J Hum Genet. 1998 May;62(5):1034-43. Fiorini M et al. BTK: 22 novel and 25 recurrent mutations in European patients with X-linked agammaglobulinemia. Hum Mutat. 2004 Mar;23(3):286. Futatani T et al. Bruton's tyrosine kinase is present in normal platelets and its absence identifies patients with X-linked agammaglobulinaemia and carrier females. Br J Haematol. 2001 Jul;114(1):141-9. Lee PP et al. Clinical characteristics and genotype-phenotype correlation in 62 patients with X-linked agammaglobulinemia. J Clin Immunol. 2010 Jan;30(1):121-31. Plebani A et al. Clinical, immunological, and molecular analysis in a large cohort of patients with X-linked agammaglobulinemia: an Italian multicenter study. Clin Immunol. 2002 Sep;104(3):221-30. Tzeng SR et al. Stability and peptide binding specificity of Btk SH2 domain: molecular basis for X-linked agammaglobulinemia. Protein Sci. 2000 Dec;9(12):2377-85.

#SampleMethodObservation
OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1germlineunknownnot providednot providednot providednot providednot providednot providednot provided

Last Updated: Sep 29, 2024